NEW YORK (GenomeWeb News) – PGXL Technologies and Silicon Biosystems today announced a deal to make Silicon Bio's DEPArray technology available through PGXL.

As a result of the partnership, clinical researchers and pharmaceutical sponsors will be able to "obtain the level of data fidelity and resolution needed in cancer biomarker discovery and translational research," the two companies said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.